LIFESTYLE
Bariatric Surgery Delivers 5x the Weight Loss of Ozempic in NYU Study
<p>Patients in the bariatric surgery cohort shed an average of <strong>25.7%</strong> of their body weight over two years, while those prescribed semaglutide or tirzepatide lost 5.3%, according to a head-to-head real-world study of 51,085 patients led by researchers at NYU Langone Health and NYC Health + Hospitals. The five-fold gap, presented at the American Society for Metabolic and Bariatric Surgery annual meeting in June 2025, complicates the popular framing of Ozempic and Wegovy as the default answer for severe obesity.</p>
<p>The catch sits in adherence, not chemistry. Lead author Avery Brown told the conference that as many as 70% of GLP-1 patients may discontinue treatment within a year, and once the weekly injections stop, much of the lost weight typically returns.</p>
<h2>The 5x Gap, Measured in Real Patients</h2>
<p>The team pulled electronic medical records covering patients with a body mass index of at least 35 who either underwent sleeve gastrectomy or Roux-en-Y gastric bypass, or filled prescriptions for injectable semaglutide or tirzepatide between 2018 and 2024. Cohorts were matched on age, BMI, and comorbidities using average-treatment-effect weighting, then tracked for total body weight change out to twenty-four months.</p>
<p>The surgical arm dropped about 58 pounds on average. The medication arm, which included anyone with at least six months of GLP-1 supply, lost roughly 12 pounds. Even patients who stayed on continuous weekly injections for a full twelve months averaged closer to 7% of total body weight, well short of the surgical figure.</p>
<p>Funding came from an NIH KL2 translational science award rather than from ASMBS directly, though the society hosted the conference and its president endorsed the findings publicly. The work is published in summary form through <a href="https://asmbs.org/news_releases/head-to-head-study-shows-bariatric-surgery-superior-to-glp-1-drugs-for-weight-loss/" target="_blank" rel="noopener">the ASMBS head-to-head presentation release</a>.</p>
<p><strong>Stats snapshot, 24-month outcomes:</strong></p>
<ul>
<li><strong>25.7%</strong> average body weight lost by surgical patients</li>
<li><strong>5.3%</strong> average body weight lost across the broader GLP-1 group</li>
<li><strong>8.9%</strong> average loss for tirzepatide patients specifically</li>
<li><strong>51,085</strong> patients in the matched real-world cohort</li>
</ul>
<figure class="wp-block-image aligncenter featured-image" style="margin:1.5em auto;text-align:center;"><img class="aligncenter" src="https://budgyapp.com/wp-content/uploads/2026/05/bariatric-surgery-vs-ozempic-weight-loss-comparison-from-nyu-real-world-study-re.webp" alt="Bariatric surgery vs Ozempic weight loss comparison from NYU real-world study results." style="width:100%;max-width:800px;height:auto;border-radius:8px;display:block;margin:0 auto;" /><figcaption style="text-align:center;font-size:0.85em;color:#888;margin-top:0.5em;">Bariatric surgery vs Ozempic weight loss comparison from NYU real-world study results.</figcaption></figure>
<h2>Why Clinical Trials and Real Pharmacies Disagree</h2>
<p>Clinical-trial readouts tell a louder story. In <a href="https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine" target="_blank" rel="noopener">Eli Lilly&#8217;s SURMOUNT-1 phase 3 results published in The New England Journal of Medicine</a>, the 15 mg dose delivered 22.5% mean weight loss across 72 weeks, with the 10 mg arm landing at 21.4% and 5 mg at 16.0%. Semaglutide trials, mainly STEP-1, produced figures near 15%. Those numbers anchor every marketing brochure and physician conversation about GLP-1 obesity therapy.</p>
<p>Trial protocols enforce something pharmacies cannot. Weekly attendance, structured titration, supply continuity, and a financial incentive to remain enrolled together produce adherence levels that real-world prescribing rarely reaches. A peer-reviewed analysis in the <em>Journal of Managed Care &; Specialty Pharmacy</em> reported that one-year persistence among obese, commercially insured adults without diabetes sat at <strong>47.1%</strong> for semaglutide. For the obesity-indicated Wegovy formulation, persistence ran from 33.2% in 2021 to 58.6% in the first half of 2024, an improvement but still far short of trial-level retention.</p>
<p>The contrast became one of the central points at the meeting.</p>
<blockquote>
<p>Clinical trials show weight loss between 15 percent and 21 percent for GLP-1s, but this study suggests that weight loss in the real world is considerably lower even for patients who have active prescriptions for an entire year.</p>
</blockquote>
<p>Brown, a surgical resident at NYU Langone Health, presented these findings alongside senior author Karan Chhabra at the ASMBS Annual Scientific Meeting on June 17, 2025.</p>
<h2>Surgery and Injection, Compared Side by Side</h2>
<p>The new study invites a direct comparison that until now has lived mostly in editorial commentary. The table below combines the new real-world figures with published trial data, peer-reviewed persistence reporting, and cost benchmarks from the same date range.</p>
<table>
<thead>
<tr>
<th>Measure</th>
<th>Bariatric Surgery</th>
<th>GLP-1 (Semaglutide / Tirzepatide)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average 2-year weight loss, real-world</td>
<td>25.7%</td>
<td>5.3%</td>
</tr>
<tr>
<td>Weight loss after 12 months of continuous use</td>
<td>One-time procedure</td>
<td>≈ 7%</td>
</tr>
<tr>
<td>Clinical-trial efficacy range</td>
<td>25% to 30% at 24 months</td>
<td>15% to 22.5% at 72 weeks</td>
</tr>
<tr>
<td>One-year medication persistence</td>
<td>Not applicable</td>
<td>33% to 58% (Wegovy cohort)</td>
</tr>
<tr>
<td>Typical US cash cost</td>
<td>$17,000 to $26,000 upfront</td>
<td>$1,000 to $1,400 per month</td>
</tr>
<tr>
<td>US insurance coverage (BMI ≥ 35 + comorbidity)</td>
<td>Widely covered</td>
<td>Often excluded for obesity</td>
</tr>
<tr>
<td>Reversibility</td>
<td>Sleeve: no; Bypass: partially</td>
<td>Stop drug, weight typically returns</td>
</tr>
</tbody>
</table>
<p>The headline 5x figure compares the full medication arm to the surgical arm. Even isolating the most adherent GLP-1 subgroup brings the gap down to roughly 3.5x, not parity.</p>
<h2>The Drop-Off Curve Few Patients Anticipate</h2>
<p>Discontinuation is the dominant lever in the real-world gap, and the reasons split across four overlapping causes that show up consistently in claims databases and patient surveys alike.</p>
<h3>How Long Patients Last on Semaglutide</h3>
<p>Median time to discontinuation for Ozempic users in <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11293763/" target="_blank" rel="noopener">a peer-reviewed analysis of commercial claims data</a> landed at 279 days. That figure includes prescriptions written for type 2 diabetes, where adherence runs higher than weight-loss-only use. Among obese commercial enrollees without diabetes, the median falls under 200 days, which lines up with Brown&#8217;s framing of <strong>70%</strong> of patients dropping treatment inside the first year.</p>
<p>Persistence has improved with each calendar year as supply stabilizes and prescribers refine dosing, but no cohort yet measured comes close to the near-universal adherence built into phase 3 trials.</p>
<h3>What Happens When the Shot Stops</h3>
<p>Once weekly injections end, appetite signaling reverts toward baseline within weeks. Published follow-up of the STEP-4 semaglutide withdrawal arm reported about two-thirds of lost weight regained within a year of cessation. That recovery curve is largely why the study&#8217;s authors flagged durability, not peak efficacy, as the surgical advantage.</p>
<p>Common drivers patients cite for stopping include:</p>
<ul>
<li>Cost shock after a payer authorization lapses or a formulary changes</li>
<li>Persistent gastrointestinal side effects past the titration phase</li>
<li>Plateaued weight loss between months six and twelve</li>
<li>Supply gaps during the 2022 to 2024 shortage stretches</li>
<li>Disrupted routine after travel, illness, or a missed pharmacy run</li>
</ul>
<h2>The Price Tag Over a Decade</h2>
<p>Sticker math tilts the comparison further. A patient paying cash for Wegovy at the current US list price of $1,349.02 per month spends roughly $16,200 a year, or about <strong>$162,000</strong> across ten years if they remain on therapy. Bariatric surgery, listed between $17,000 and $26,000 for sleeve or bypass, is one upfront bill, often with a substantial portion covered by insurance for patients who meet BMI and comorbidity thresholds.</p>
<p>Most commercial plans cover bariatric procedures when a patient documents BMI of 35 or above with at least one obesity-related condition, or BMI of 40 without comorbidities. Coverage for GLP-1 drugs prescribed for obesity is far thinner. Medicare is statutorily barred from paying for weight-loss drugs, and a growing list of employers pulled GLP-1s from their formularies as 2024 and 2025 benefit budgets tightened. State legislators have moved against unauthorized compounded versions too, including <a href="https://budgyapp.com/colorado-crackdown-misleading-weight-loss-drugs/" target="_blank" rel="noopener">Colorado&#8217;s crackdown on misleading compounded weight loss drugs</a>, which closes off the cheapest informal channel many cash-pay patients had been using.</p>
<p>The arithmetic flips the cost-effectiveness conversation. Surgery&#8217;s price compresses into year one; medication cost compounds for as long as the patient stays on therapy. Patients who quit mid-course absorb the months of treatment and the weight rebound, an outcome that ranks poorly on either spending or health terms.</p>
<h2>Matching Patient to Treatment</h2>
<p>The study&#8217;s authors have been careful not to write off GLP-1s. Senior author Karan Chhabra, a bariatric surgeon at NYU Grossman School of Medicine, outlined future work around figuring out which patients benefit most from which path, and what providers can do to improve GLP-1 outcomes when the drug is appropriate. <a href="https://nyulangone.org/news/nyu-langone-experts-present-latest-research-weight-loss-surgery-outcomes-techniques-2025-asmbs-annual-meeting" target="_blank" rel="noopener">NYU Langone&#8217;s published research summary from the 2025 meeting</a> lists adherence optimization as the next study priority.</p>
<p>Several patient profiles fit GLP-1 therapy better than surgery:</p>
<ul>
<li>Adults with type 2 diabetes who need glycemic control alongside weight reduction, where semaglutide brings additional cardiovascular and renal benefit</li>
<li>Patients in the overweight or class I obesity range whose BMI sits below the surgical threshold</li>
<li>Patients for whom general anaesthesia or abdominal surgery carries elevated procedural risk</li>
<li>Patients who, after counseling, prefer reversible therapy and accept the cost of long-term use</li>
</ul>
<p>Surgery tends to fit a different profile:</p>
<ul>
<li>Patients with BMI of 40 or higher, or 35 with a qualifying comorbidity, who have not sustained results from medical weight loss</li>
<li>Patients with severe metabolic disease where rapid, durable BMI reduction improves life expectancy and lowers downstream medical spending</li>
<li>Patients who cannot afford or sustain a multi-year GLP-1 regimen and have stable psychosocial support for post-operative recovery</li>
</ul>
<p>The honest reading of the evidence is that the two interventions are not interchangeable. They sit on the same shelf for marketing convenience; the clinical decisions, costs, recovery, and risk profiles look almost nothing alike. Surgery&#8217;s advantage doesn&#8217;t need a monthly refill to hold.</p>
<h2>Frequently Asked Questions</h2>
<h3>How Big Was the NYU Comparison Group?</h3>
<p>Researchers analyzed 51,085 patients with BMI of 35 or above who either had sleeve gastrectomy or gastric bypass, or were prescribed injectable semaglutide or tirzepatide between 2018 and 2024. Cohorts were matched on age, BMI, and comorbidities using average-treatment-effect weighting.</p>
<h3>Why Do Most GLP-1 Patients Stop Taking the Drug?</h3>
<p>Side effects, cost, plateaued results, and supply disruption are the four most common reasons. Median time to discontinuation runs near 200 days for obese patients without diabetes, and the lead author told the ASMBS conference that as many as 70% of patients may stop within the first year.</p>
<h3>Does Insurance Cover GLP-1 Drugs for Weight Loss?</h3>
<p>Often, no. Most US commercial plans cover semaglutide when it is prescribed for type 2 diabetes but exclude weight-loss-only prescriptions. Medicare is barred by federal law from paying for weight-loss drugs. A growing number of employers dropped GLP-1 coverage from 2024 onward as monthly spend rose.</p>
<h3>Is Bariatric Surgery Reversible?</h3>
<p>Sleeve gastrectomy is not reversible because a portion of the stomach is permanently removed. Roux-en-Y gastric bypass can be partially reversed in rare clinical cases, but the procedure is intended to be permanent and most surgeons treat it that way.</p>
<h3>Can a Patient Try GLP-1 Drugs First and Then Move to Surgery?</h3>
<p>Yes. A separate retrospective study presented at the same ASMBS meeting found that patients who used GLP-1 therapy before bariatric surgery still achieved comparable post-operative weight loss to surgery-only patients. Some surgical programs now include short-course GLP-1 use as part of pre-operative optimization.</p>
<h3>Does Tirzepatide Outperform Semaglutide?</h3>
<p>Yes, marginally. In SURMOUNT-1 the 15 mg dose achieved up to 22.5% weight loss, while semaglutide trials produced about 15%. In the new real-world data, the dual-action drug averaged 8.9% two-year loss, ahead of semaglutide users but still well behind surgical outcomes.</p>
<p><script type="application/ld+json">
{
 "@context": "https://schema.org",
 "@type": "FAQPage",
 "mainEntity": [
 {"@type":"Question","name":"How Big Was the NYU Comparison Group?","acceptedAnswer":{"@type":"Answer","text":"Researchers analyzed 51,085 patients with BMI of 35 or above who either had sleeve gastrectomy or gastric bypass, or were prescribed injectable semaglutide or tirzepatide between 2018 and 2024. Cohorts were matched on age, BMI, and comorbidities using average-treatment-effect weighting."}},
 {"@type":"Question","name":"Why Do Most GLP-1 Patients Stop Taking the Drug?","acceptedAnswer":{"@type":"Answer","text":"Side effects, cost, plateaued results, and supply disruption are the four most common reasons. Median time to discontinuation runs near 200 days for obese patients without diabetes, and the lead author told the ASMBS conference that as many as 70% of patients may stop within the first year."}},
 {"@type":"Question","name":"Does Insurance Cover GLP-1 Drugs for Weight Loss?","acceptedAnswer":{"@type":"Answer","text":"Often, no. Most US commercial plans cover semaglutide when it is prescribed for type 2 diabetes but exclude weight-loss-only prescriptions. Medicare is barred by federal law from paying for weight-loss drugs. A growing number of employers dropped GLP-1 coverage from 2024 onward as monthly spend rose."}},
 {"@type":"Question","name":"Is Bariatric Surgery Reversible?","acceptedAnswer":{"@type":"Answer","text":"Sleeve gastrectomy is not reversible because a portion of the stomach is permanently removed. Roux-en-Y gastric bypass can be partially reversed in rare clinical cases, but the procedure is intended to be permanent and most surgeons treat it that way."}},
 {"@type":"Question","name":"Can a Patient Try GLP-1 Drugs First and Then Move to Surgery?","acceptedAnswer":{"@type":"Answer","text":"Yes. A separate retrospective study presented at the same ASMBS meeting found that patients who used GLP-1 therapy before bariatric surgery still achieved comparable post-operative weight loss to surgery-only patients. Some surgical programs now include short-course GLP-1 use as part of pre-operative optimization."}},
 {"@type":"Question","name":"Does Tirzepatide Outperform Semaglutide?","acceptedAnswer":{"@type":"Answer","text":"Yes, marginally. In SURMOUNT-1 the 15 mg dose achieved up to 22.5% weight loss, while semaglutide trials produced about 15%. In the new real-world data, the dual-action drug averaged 8.9% two-year loss, ahead of semaglutide users but still well behind surgical outcomes."}}
 ]
}
</script></p>
<p><strong><em>Disclaimer:</em></strong> <em>This article is for informational purposes only and is not medical advice. Weight loss decisions, including the choice between GLP-1 medications and bariatric surgery, carry clinical risks that depend on individual health history. Consult a qualified physician or licensed bariatric surgeon before starting, stopping, or switching any treatment. Figures and study data are accurate as of publication on May 28, 2026.</em></p>